Role of Vitamin D in Rheumatoid Arthritis

  • Mattia BellanEmail author
  • Pier Paolo Sainaghi
  • Mario Pirisi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 996)


Vitamin D is a fat soluble hormone, with a well described role in bone health and calcium/phosphate metabolism. Recent evidences have related vitamin D to other physiological functions and pathological conditions. Specifically, vitamin D has widely proven activities on immune system and evidences suggest that it may be implicated in the pathogenesis of rheumatoid arthritis (RA). The relationship between vitamin D and RA is complex, also because a deficitary vitamin D status, which is very common in RA patients, can contribute to the increased risk of osteoporosis typical of RA. In this chapter, will be described and discussed the main aspects of the relationship between RA and vitamin D.


Vitamin D Rheumatoid arthritis Hypovitaminosis D 

List of Abbreviations

1,25(OH)2 vitamin D

1,25-dihydroxyvitamin D

25(OH) vitamin D

25-hydroxyvitamin D


Antigen presenting cells


Autoimmune rheumatic diseases


Bone mineral density


Bone mass index


Cluster of differentiation


CCAAT-enhancer-binding proteins


C-reactive protein


Cytotoxic T-Lymphocyte Antigen 4


Dendritic cells


Dickkopf-related protein 1


Epidermal growth factor receptor


Forkhead box P3


Human immunodeficiency virus


Inflammatory bowel diseases


Interferon γ




International units


Janus kinase


Mitogen-activated protein kinase


Major histocompatibility complex


Multiple sclerosis


nuclear factor kappa-light-chain-enhancer of activated B cells




Parathyroid hormone


Rheumatoid Arthritis


Receptor activator of nuclear factor kappa-B


Receptor activator of nuclear factor kappa-B ligand


Randomized clinical trial


Retinoid X receptor


Systemic lupus erythematosus


Signal transducer and activator of transcription 1


Type 1 diabetes mellitus


Transforming growth factor α


T helper


Toll like receptor


Tumor necrosis factor α


Regulatory T cells


Undifferentiated connective tissue disease




Vitamin D receptor


Vitamin D Responsive Elements


  1. 1.
    Rosenheim O, Webster TA (1927) The relation of cholesterol to vitamin D. Biochem J 21:127–129PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Avioli LV (1969) Absorption and metabolism of vitamin D3 in man. Am J Clin Nutr 22:437–446PubMedGoogle Scholar
  3. 3.
    Ohyama Y, Yamasaki T (2004) Eight cytochrome P450s catalyze vitamin D metabolism. Front Biosci 9:3007–3018PubMedCrossRefGoogle Scholar
  4. 4.
    DeLuca HF (1969) 25-Hydroxycholecalciferol, the probable metabolically active form of vitamin D. Isolation, identification, and subcellular location. Am J Clin Nutr 22:412–424PubMedGoogle Scholar
  5. 5.
    Daiger SP, Schanfield MS, Cavalli-Sforza LL (1975) Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci U S A 72:2076–2080PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Zerwekh JE (2008) Blood biomarkers of vitamin D status. Am J Clin Nutr 87:1087–191SGoogle Scholar
  7. 7.
    Norman AW (1971) Evidence for a new kidney-produced hormone, 1,25-dihydroxycholecalciferol, the proposed biologically active form of vitamin D. Am J Clin Nutr 24:1346–1351PubMedGoogle Scholar
  8. 8.
    Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M (2001) Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86:888–894PubMedGoogle Scholar
  9. 9.
    Adams JS, Hewison M (2012) Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 523:95–102PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM (1992) Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446–449PubMedCrossRefGoogle Scholar
  11. 11.
    Christakos S, Lieben L, Masuyama R, Carmeliet G (2014) Vitamin D endocrine system and the intestine. Bonekey Rep 3:496PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Jeon US (2008) Kidney and calcium homeostasis. Electrolyte Blood Press 6:68–76PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Kim S, Yamazaki M, Zella LA, Meyer MB, Fretz JA, Shevde NK, Pike JW (2007) Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 103:430–434PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055PubMedCrossRefGoogle Scholar
  15. 15.
    Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM (1992) Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 89:8097–8101PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Zgaga L, Theodoratou E, Farrington SM, Agakov F, Tenesa A, Walker M, Knox S, Wallace AM, Cetnarskyj R, McNeill G, Kyle J, Porteous ME, Dunlop MG, Campbell H (2011) Diet, environmental factors, and lifestyle underlie the high prevalence of vitamin D deficiency in healthy adults in Scotland, and supplementation reduces the proportion that are severely deficient. J Nutr 141:1535–1542PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Matsuoka LY, Wortsman J, Haddad JG, Hollis BW (1989) In vivo threshold for cutaneous synthesis of vitamin D3. J Lab Clin Med 114:301–305PubMedGoogle Scholar
  18. 18.
    Wacker M, Holick MF (2013) Sunlight and vitamin D: a global perspective for health. Dermatoendocrinol 5:51–108PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Hyppönen E, Power C (2007) Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 85:860–868PubMedGoogle Scholar
  20. 20.
    Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF (1987) Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab 64:1165–1168PubMedCrossRefGoogle Scholar
  21. 21.
    Clemens TL, Henderson SL, Adams JS, Holick MF (1982) Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1:74–76PubMedCrossRefGoogle Scholar
  22. 22.
    MacLaughlin J, Holick MF (1985) Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 76:1536–1538PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Holick MF, Matsuoka LY, Wortsman J (1989) Age, vitamin D, and solar ultraviolet. Lancet 2:1104–1105PubMedCrossRefGoogle Scholar
  24. 24.
    Snijder MB, van Dam RM, Visser M, Deeg DJ, Dekker JM, Bouter LM, Seidell JC, Lips P (2005) Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab 90:4119–4123PubMedCrossRefGoogle Scholar
  25. 25.
    Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000) Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72:690–693PubMedGoogle Scholar
  26. 26.
    Hyppönen E, Power C (2006) Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 29:2244–2246PubMedCrossRefGoogle Scholar
  27. 27.
    Thompson GR, Lewis B, Booth CC (1966) Absorption of vitamin D3-3H in control subjects and patients with intestinal malabsorption. J Clin Invest 45:94–102PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Karefylakis C, Näslund I, Edholm D, Sundbom M, Karlsson FA, Rask E (2014) Vitamin D status 10 years after primary gastric bypass: gravely high prevalence of hypovitaminosis D and raised PTH levels. Obes Surg 24:343–348PubMedCrossRefGoogle Scholar
  29. 29.
    Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, Thummel KE (2006) Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 116:1703–1712PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281PubMedCrossRefGoogle Scholar
  31. 31.
    Heaney RP (2004) Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 80:1706–179SGoogle Scholar
  32. 32.
    Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest 116:2062–2072PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Malabanan AO, Turner AK, Holick MF (1998) Severe generalized bone pain and osteoporosis in a premenopausal black female: effect of vitamin D replacement. J Clin Densitometr 1:201–204CrossRefGoogle Scholar
  34. 34.
    Plotnikoff GA, Quigley JM (2003) Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 78:1463–1470PubMedCrossRefGoogle Scholar
  35. 35.
    Boland R (1986) Role of vitamin D in skeletal muscle function. Endocr Rev 7:434–448PubMedCrossRefGoogle Scholar
  36. 36.
    Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7:439–443PubMedCrossRefGoogle Scholar
  37. 37.
    Bischoff-Ferrari H (2009) Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary? Best Pract Res Clin Rheumatol 23:789–795PubMedCrossRefGoogle Scholar
  38. 38.
    Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Manson JE, Mayne ST, Ross AC, Shapses SA, Taylor CL (2012) IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 97:1146–1152PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930PubMedCrossRefGoogle Scholar
  40. 40.
    Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, El-Hajj Fuleihan G, Josse RG, Lips P, Morales-Torres J (2009) IOF committee of scientific advisors (CSA) nutrition working group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 20:1807–1820PubMedCrossRefGoogle Scholar
  41. 41.
    Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81:353–373PubMedCrossRefGoogle Scholar
  42. 42.
    Hirani V, Primatesta P (2005) Vitamin D concentrations among people aged 65 years and over living in private households and institutions in England: population survey. Age Ageing 34:485–491PubMedCrossRefGoogle Scholar
  43. 43.
    Simonelli C, Weiss TW, Morancey J, Swanson L, Chen YT (2005) Prevalence of vitamin D inadequacy in a minimal trauma fracture population. Curr Med Res Opin 21:1069–1074PubMedCrossRefGoogle Scholar
  44. 44.
    Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 14:577–582PubMedCrossRefGoogle Scholar
  45. 45.
    Perin A, Zanatta E, Pigatto E, Carniello S, Cozzi F (2012) Hypovitaminosis D in an hospitalized old population of Western Friuli. Reumatismo 64:166–171PubMedCrossRefGoogle Scholar
  46. 46.
    Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF (2012) Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep 14:224–230PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Sainaghi PP, Bellan M, Carda S, Cerutti C, Sola D, Nerviani A, Molinari R, Cisari C, Avanzi GC (2012) Hypovitaminosis D and response to cholecalciferol supplementation in patients with autoimmune and non-autoimmune rheumatic diseases. Rheumatol Int 32:3365–3372PubMedCrossRefGoogle Scholar
  48. 48.
    Mouyis M, Ostor AJ, Crisp AJ, Ginawi A, Halsall DJ, Shenker N, Poole KE (2008) Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology (Oxford) 47:1348–1351CrossRefGoogle Scholar
  49. 49.
    Stoll D, Dudler J, Lamy O, Hans D, So A, Krieg MA, Aubry-Rozier B (2011) High prevalence of hypovitaminosis D in a Swiss rheumatology outpatient population. Swiss Med Wkly 141:13196Google Scholar
  50. 50.
    Reusch J, Ackermann H, Badenhoop K (2009) Cyclic changes of vitamin D and PTH are primarily regulated by solar radiation: 5-year analysis of a German (50 degrees N) population. Horm Metab Res 41:402–407PubMedCrossRefGoogle Scholar
  51. 51.
    Jacques PF, Felson DT, Tucker KL, Mahnken B, Wilson PW, Rosenberg IH, Rush D (1997) Plasma 25-hydroxyvitamin D and its determinants in an elderly population sample. Am J Clin Nutr 66:929–936PubMedGoogle Scholar
  52. 52.
    Atwa MA, Balata MG, Hussein AM, Abdelrahman NI, Elminshawy HH (2013) Serum 25-hydroxyvitamin D concentration in patients with psoriasis and rheumatoid arthritis and its association with disease activity and serum tumor necrosis factor-alpha. Saudi Med J 34:806–813PubMedGoogle Scholar
  53. 53.
    Als OS, Riis B, Christiansen C (1987) Serum concentration of vitamin D metabolites in rheumatoid arthritis. Clin Rheumatol 6:238–243PubMedCrossRefGoogle Scholar
  54. 54.
    Nielen MM, van Schaardenburg D, Lems WF, van de Stadt RJ, de Koning MH, Reesink HW, Habibuw MR, van der Horst-Bruinsma IE, Twisk JW, Dijkmans BA (2006) Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum 54:3719–3720PubMedCrossRefGoogle Scholar
  55. 55.
    Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, Sulli A, Paolino S, Seriolo B (2006) Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: northern versus southern Europe. Clin Exp Rheumatol 24:702–704PubMedGoogle Scholar
  56. 56.
    Grazio S, Naglić ĐB, Anić B, Grubišić F, Bobek D, Bakula M, Kavanagh HS, Kuna AT, Cvijetić S (2015) Vitamin D serum level, disease activity and functional ability in different rheumatic patients. Am J Med Sci 349:46–49PubMedCrossRefGoogle Scholar
  57. 57.
    Kerr GS, Sabahi I, Richards JS, Caplan L, Cannon GW, Reimold A, Thiele GM, Johnson D, Mikuls TR (2011) Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol 38:53–59PubMedCrossRefGoogle Scholar
  58. 58.
    Zheng ZH, Gao CC, Wu ZZ, Liu SY, Li TF, Gao GM, Liu ZS (2016) High prevalence of hypovitaminosis D of patients with autoimmune rheumatic diseases in China. Am J Clin Exp Immunol 5:48–54PubMedPubMedCentralGoogle Scholar
  59. 59.
    Sainaghi PP, Bellan M, Antonini G, Bellomo G, Pirisi M (2011) Unsuppressed parathyroid hormone in patients with autoimmune/inflammatory rheumatic diseases: implications for vitamin D supplementation. Rheumatology (Oxford) 50:2290–2296CrossRefGoogle Scholar
  60. 60.
    Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D, Lips P (2013) Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab 98:1283–1304CrossRefGoogle Scholar
  61. 61.
    Sainaghi PP, Bellan M, Nerviani A, Sola D, Molinari R, Cerutti C, Pirisi M (2013) Superiority of a high loading dose of cholecalciferol to correct hypovitaminosis d in patients with inflammatory/autoimmune rheumatic diseases. J Rheumatol 40:166–172PubMedCrossRefGoogle Scholar
  62. 62.
    Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303:1815–1822PubMedCrossRefGoogle Scholar
  63. 63.
    Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, Dick W, Willett WC, Egli A (2016) Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med 176:175–183PubMedCrossRefGoogle Scholar
  64. 64.
    Hooyman JR, Melton LJ III, Nelson AM, O’Fallon WM, Riggs BL (1984) Fractures after rheumatoid arthritis: a population-based study. Arthritis Rheum 27:1353–1361PubMedCrossRefGoogle Scholar
  65. 65.
    Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801–806PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL et al (2010) Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 12:R154PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum 43:522–530PubMedCrossRefGoogle Scholar
  68. 68.
    Vis M, Haavardsholm EA, Bøyesen P, Haugeberg G, Uhlig T, Hoff M et al (2011) High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int 22:2413–2419PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    EPOS study group (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716–724CrossRefGoogle Scholar
  70. 70.
    Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC et al (2005) Risk factors for a first-incident radiographic vertebral fracture in women at least 65 years of age: the study of osteoporotic fractures. J Bone Miner Res 20:131–140PubMedCrossRefGoogle Scholar
  71. 71.
    Geusens PP, Lems WF (2011) Osteoimmunology and osteoporosis. Arthritis Res Ther 13:242PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Takayanagi H (2009) Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5:667–676PubMedCrossRefGoogle Scholar
  73. 73.
    Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276–1287PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Lories RJ, Luyten FP (2009) Osteoimmunology: Wnt antagonists: for better or worse? Nat Rev Rheumatol 5:420–421PubMedCrossRefGoogle Scholar
  75. 75.
    Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP (2011) Early effects of Il-6 receptor inhibition on bone homeostasis. Clin Exp Rheumatol 29:921–925PubMedGoogle Scholar
  76. 76.
    Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRefGoogle Scholar
  78. 78.
    Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R (2005) Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177–181PubMedCrossRefGoogle Scholar
  79. 79.
    van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777PubMedCrossRefGoogle Scholar
  80. 80.
    Bellan M, Pirisi M, Sainaghi PP (2014) Osteoporosis in rheumatoid arthritis: role of the vitamin D/parathyroid hormone system. Rev Bras Reumatol 55:256–263PubMedCrossRefGoogle Scholar
  81. 81.
    Ranganathan P (2009) Genetics of bone loss in rheumatoid arthritis – role of vitamin D receptor polymorphisms. Rheumatology 48:342–343PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Rass P, Pákozdi A, Lakatos P, Zilahi E, Sipka S, Szegedi G et al (2006) Vitamin D receptor gene polymorphism in rheumatoid arthritis and associated osteoporosis. Rheumatol Int 26:964–971PubMedCrossRefGoogle Scholar
  83. 83.
    Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T (1983) Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha, 25-dihydroxyvitamin D3. Endocrinology 113:1950–1957PubMedCrossRefGoogle Scholar
  84. 84.
    DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC (2013) Review: the role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol 39:458–484PubMedCrossRefGoogle Scholar
  85. 85.
    Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229–238PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T (1986) Effect of 1 alpha (OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner 1:187–192PubMedGoogle Scholar
  87. 87.
    Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D (2008) Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 10:185–197PubMedCrossRefGoogle Scholar
  88. 88.
    Norman AW, Frankel JB, Heldt AM, Grodsky GM (1980) Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209:823–882PubMedCrossRefGoogle Scholar
  89. 89.
    Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, Murad MH, Kovacs CS (2012) The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 33:456–492PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM (1983) Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57:1308–1310PubMedCrossRefGoogle Scholar
  91. 91.
    Yu XP, Hustmyer FG, Garvey WT, Manolagas SC (1991) Demonstration of a 1,25-dihydroxyvitamin D3-responsive protein in human lymphocytes: immunologic crossreactivity and inverse regulation with the vitamin D receptor. Proc Natl Acad Sci U S A 88:8347–8351PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Walters MR (1992) Newly identified actions of the vitamin D endocrine system. Endocr Rev 13:719–764PubMedGoogle Scholar
  93. 93.
    Bikle DD (2008) Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens 179:348–352CrossRefGoogle Scholar
  94. 94.
    Xu H, Soruri A, Gieseler RKH, Peters JH (1993) 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol 38:535–540PubMedCrossRefGoogle Scholar
  95. 95.
    Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, Goleva E (2012) Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 188:2127–2135PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Kreutz M, Andressen R (1990) Induction of human monocyte to macrophage maturation in vitro by 1,25-dihydroxyvitamin D3. Blood 76:2457–2461PubMedGoogle Scholar
  97. 97.
    Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, Allavena P, Di Carlo V (2000) Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164:4443–4451PubMedCrossRefGoogle Scholar
  98. 98.
    Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R (2000) Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 270:701–708PubMedCrossRefGoogle Scholar
  99. 99.
    Gauzzi MC, Purificato C, Donato K, Jin Y, Wang L, Daniel KC, Maghazachi AA, Belardelli F, Adorini L, Gessani S (2005) Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 174:270–276PubMedCrossRefGoogle Scholar
  100. 100.
    Monkawa T, Yoshida T, Hayashi M, Saruta T (2000) Identification of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression in macrophages. Kidney Int 58:559–568PubMedCrossRefGoogle Scholar
  101. 101.
    Smith SJ, Hayes ME, Selby PL, Mawer EB (1999) Autocrine control of vitamin D metabolism in synovial cells from arthritic patients. Ann Rheum Dis 58:372–378PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M (2003) Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvitamin D3 by human dendritic cells. Blood 102:3314–3316PubMedCrossRefGoogle Scholar
  103. 103.
    Nelson CD, Reinhardt TA, Beitz DC, Lippolis JD (2010) In vivo activation of the intracrine vitamin D pathway in innate immune cells and mammary tissue during a bacterial infection. PLoS One 5:e15469PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    White JH (2012) Regulation of intracrine production of 1,25-dihydroxyvitamin D and its role in innate immune defense against infection. Arch Biochem Biophys 523:58–63PubMedCrossRefGoogle Scholar
  105. 105.
    Overbergh L, Stoffels K, Waer M, Verstuyf A, Bouillon R, Mathieu C (2006) Immune regulation of 25-hydroxyvitamin D-1alpha-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-gamma-mediated induction. J Clin Endocrinol Metab 91:3566–3574PubMedCrossRefGoogle Scholar
  106. 106.
    Stoffels K, Overbergh L, Giulietti A, Verlinden L, Bouillon R, Mathieu C (2006) Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res 21:37–47PubMedCrossRefGoogle Scholar
  107. 107.
    Adams JS, Gacad MA (1985) Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 161:755–765PubMedCrossRefGoogle Scholar
  108. 108.
    Chen SGP, Chen XX, Gu YY, Chen S, Lipsky PE (2007) Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647PubMedCrossRefGoogle Scholar
  109. 109.
    Cippitelli M, Fionda C, Di Bona D, Di Rosa F, Lupo A, Piccoli M, Frati L, Santoni A (2002) Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J Immunol 168:1154–1166PubMedCrossRefGoogle Scholar
  110. 110.
    Rigby WF, Denome S, Fanger MW (1987) Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 79:1659–1664PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Cantorna MT, Woodward WD, Hayes CE, DeLuca HF (1998) 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 160:5314–5319PubMedGoogle Scholar
  112. 112.
    Sloka S, Silva C, Wang J, Yong VW (2011) Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation 8:56PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, Ichiyama K, Yoshimura A, Steinman L, Christakos S, Youssef S (2011) 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 31:3653–3669PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Zhang H, Shih DQ, Zhang X (2013) Mechanisms underlying effects of 1,25-Dihydroxyvitamin D3 on the Th17 cells. Eur J Microbiol Immunol 3:237–240CrossRefGoogle Scholar
  115. 115.
    Jeffery LE, Wood AM, Qureshi OS, Hou TZ, Gardner D, Briggs Z, Kaur S, Raza K, Sansom DM (2012) Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J Immunol 189:5155–5164PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358:1500–1503PubMedCrossRefGoogle Scholar
  117. 117.
    Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C (2014) Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71:306–314PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Pappa HM, Grand RJ, Gordon CM (2006) Report on the vitmin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 12:1162–1174PubMedCrossRefGoogle Scholar
  119. 119.
    Müller K, Kriegbaum NJ, Baslund B, Sørensen OH, Thymann M, Bentzen K (1995) Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 14:397–400PubMedCrossRefGoogle Scholar
  120. 120.
    Zold E, Szodoray P, Gaal J, Kappelmayer J, Csathy L, Gyimesi E, Zeher M, Szegedi G, Bodolay E (2008) Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 10:R123PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG, Study I W's H (2004) Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa women’s health study. Arthritis Rheum 50:72–77PubMedCrossRefGoogle Scholar
  122. 122.
    Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E (2008) Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 67:530–535PubMedCrossRefGoogle Scholar
  123. 123.
    Hiraki LT, Arkema EV, Cui J, Malspeis S, Costenbader KH, Karlson EW (2014) Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis. Rheumatology (Oxford) 53:2243–2248CrossRefGoogle Scholar
  124. 124.
    Tizaoui K, Hamzaoui K (2015) Association between VDR polymorphisms and rheumatoid arthritis disease: Systematic review and updated meta-analysis of case-control studies. Immunobiology 220:807–816PubMedCrossRefGoogle Scholar
  125. 125.
    Fakharan M, Haghighi A, Arabi M, Loghman M (2014) Investigating the levels of serum vitamin d in patients with rheumatoid arthritis referred to rasoul-akram hospital during 2011–2012. Iran J Med Sci 39:476–479PubMedPubMedCentralGoogle Scholar
  126. 126.
    Abourazzak FE, Talbi S, Aradoini N, Berrada K, Keita S, Hazry T (2015) 25-Hydroxy vitamin D and its relationship with clinical and laboratory parameters in patients with rheumatoid arthritis. Clin Rheumatol 34:353–357PubMedCrossRefGoogle Scholar
  127. 127.
    Sabbagh Z, Markland J, Vatanparast H (2013) Vitamin D status is associated with disease activity among rheumatology outpatients. Forum Nutr 5:2268–2275Google Scholar
  128. 128.
    van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Cornelissen F, van Leeuwen JP, Hazes JM, Dolhain RJ, Bakx PA, Colin EM, Lubberts E (2012) TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation. Ann Rheum Dis 71:606–612PubMedCrossRefGoogle Scholar
  129. 129.
    Laragione T, Shah A, Gulko PS (2012) The vitamin D receptor regulates rheumatoid arthritis synovial fibroblast invasion and morphology. Mol Med 18:194–200PubMedGoogle Scholar
  130. 130.
    Luo J, Wen H, Guo H, Cai Q, Li S, Li X (2013) 1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis. Biomed Res Int 2013:101805PubMedPubMedCentralGoogle Scholar
  131. 131.
    Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D, Pavlica L, Stefanovic D (1999) Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 17:453–456PubMedGoogle Scholar
  132. 132.
    Gopinath K, Danda D (2011) Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial. Int J Rheum Dis 14:332–339PubMedCrossRefGoogle Scholar
  133. 133.
    Hein G, Oelzner P (2000) Vitamin D metabolites in rheumatoid arthritis: findings – hypotheses – consequences. Z Rheumatol 1:28–32CrossRefGoogle Scholar
  134. 134.
    Hansen KE, Bartels CM, Gangnon RE, Jones AN, Gogineni J (2014) An evaluation of high-dose vitamin D for rheumatoid arthritis. J Clin Rheumatol 20:112–114PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Fairney A, Straffen AM, May C, Seifert MH (1987) Vitamin D metabolites in synovial fluid. Ann Rheum Dis 46:370–374PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Mattia Bellan
    • 1
    • 2
    Email author
  • Pier Paolo Sainaghi
    • 2
  • Mario Pirisi
    • 1
    • 2
  1. 1.Department of Translational MedicineUniversità del Piemonte Orientale UPONovaraItaly
  2. 2.Immunorheumatology Unit, Internal Medicine DivisionAOU Maggiore della CaritàNovaraItaly

Personalised recommendations